Abbvie Inc. has described new proteolysis targeting chimera (PROTA) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to tyrosine protein phosphatase nonreceptor type 2 (PTPN2)-targeting moiety reported to be useful for the treatment of cancer, diabetes type 2 and nonalcoholic steatohepatitis.